Triokit

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Triokit

Quick Facts

Property Description
Active Ingredients [INN] Azithromycin, Fluconazole, Secnidazole
Form Tablet (Oral)
Pharmacological Class Broad-Spectrum Antimicrobial Agent
Strategy Triple Therapy Fixed-Dose Combination
Regulatory Status Prescription Only

What Type of Medicine is Triokit? (Definition and Classification)

Triokit is the commercial designation for a prescription-only Fixed-Dose Combination (FDC) medicinal product, structurally classified as a Broad-Spectrum Antimicrobial Agent designed for oral administration in a tablet form. The essence of the medicine is its strategic, co-formulated delivery of three distinct agents in a single unit. Its entirely synthetic active ingredients—Azithromycin, Fluconazole, and Secnidazole—are integrated to provide comprehensive coverage across multiple microbial domains. This specific combination structure is clinically recognized for its application in the syndromic management of complex infections, a focus that differentiates its clinical positioning.

The Triple Therapy Composition of Triokit (Ingredients and Structure)

The composition of Triokit is a triple-agent blend formulated to attack different microbial threats simultaneously. It combines Azithromycin, a macrolide antibiotic, Fluconazole, a member of the triazole antifungal class, and Secnidazole, a nitroimidazole antiprotozoal/antibacterial agent. The strategic choice of these three agents is crucial, as each component possesses a distinct mechanism of effect. For instance, Azithromycin's primary mechanism involves inhibiting protein synthesis in susceptible bacteria, a well-established function of the macrolide class. This foundational knowledge confirms the medicine is specifically packaged for simplified, multi-target treatment.

General Purpose and Anti-Infective Strategy (High-Level Utility)

The primary purpose of Triokit is to provide comprehensive anti-infective coverage utilizing a triple therapy strategy. This formulation is designed to efficiently manage complex infectious scenarios, such as polymicrobial infections, where multiple classes of pathogens may be involved. The strategic benefit of this triple-action delivery is its potential to achieve excellent therapeutic effectiveness and enhance patient compliance. The combination design simplifies the regimen, offering a single-course foundation for treatment that ensures robust and coordinated therapeutic action across a broad microbial spectrum.

Regulatory References

  1. NIH MedlinePlus: Azithromycin
  2. NIH MedlinePlus: Secnidazole

What side effects are possible with Triokit?

Possible side effects and safety information

The official safety documentation for this fixed-dose combination (Azithromycin, Fluconazole, Secnidazole) classifies potential side effects based on system-organ classes and frequency, derived from the regulatory labels of the individual components.

Adverse Reactions Scope and Frequency

The most commonly documented adverse reactions affect the Gastrointestinal System, often categorized as common (incidence ge 1%) in regulatory documents. These include nausea, vomiting, abdominal pain, diarrhea, and dysgeusia (taste changes).

System-Organ Class Examples of Officially Listed Adverse Reactions
Gastrointestinal Nausea, Vomiting, Diarrhea, Abdominal pain
Nervous System Headache, Dizziness
Hepatobiliary Abnormal liver function, Hepatitis, Cholestatic jaundice

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions, though rare, are explicitly documented in regulatory sources and necessitate attention. These risks include severe hepatotoxicity (liver failure), life-threatening cardiac arrhythmias such as QT prolongation and Torsades de pointes, and severe skin conditions like Stevens-Johnson Syndrome (SJS).

Safety labeling also defines specific limitations. For instance, the medicine is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction linked to prior macrolide use. Furthermore, due to the Secnidazole component, co-administration with alcohol may result in a disulfiram-like reaction, which involves systemic symptoms like flushing and changes in heart rate. The official documentation notes that allergic symptoms may recur due to the long tissue half-life of Azithromycin and that Clostridioides difficile-Associated Diarrhea (CDAD) can develop up to two months after antibacterial therapy is completed.

Overdose and Emergency Response

Overdose and When to Seek Help

Triokit is a combination medication containing an antifungal (fluconazole) and two antibiotics (azithromycin and secnidazole). Overdose situations with combination products can result in magnified symptoms from any of the individual components.

Documented Overdose Profile

Symptoms associated with consuming too much of the drug components are primarily characterized by pronounced effects on the gastrointestinal and cardiovascular systems. These may include severe nausea, vomiting, diarrhea, and significant abdominal discomfort.

Less common but severe risks from the active components, particularly at toxic doses, involve potential damage to the liver and central nervous system. Liver-related toxicity can manifest as yellowing of the skin or eyes (jaundice), while central nervous system effects may include severe dizziness, unsteadiness, or, in extreme cases, seizures.

Required Emergency Actions

Classification Manifestation/Required Action
Cardiovascular Risk Irregular or rapid heart rate (palpitations), fainting (syncope)
Organ Toxicity Jaundice, severe rash, or peeling skin
Procedural Action Seek emergency medical attention immediately if an overdose is suspected or if severe, unusual symptoms occur. Always carry the medicine packaging to the healthcare provider.

Summary

If you have taken more than the prescribed dosage, or if severe, alarming symptoms develop, you should immediately contact emergency medical services or a poison control center. Never delay seeking help. Clinical management of an overdose is generally supportive, focused on monitoring vital signs, and addressing specific severe symptoms.

Therapeutic Uses of Triokit

What Triokit Treats: Main Uses and Benefits

This fixed-dose combination is commonly used to address infectious episodes involving polymicrobial infections in the lower genital tract, which may include bacterial vaginosis, trichomoniasis, and vaginal candidiasis. It is also relevant for mixed infections with Chlamydia or Neisseria. The product may be part of symptomatic management where additional support is needed to address these diverse microbial concerns.


Symptomatic Relief and Treatment Contexts

The medication is relevant for easing symptom clusters that may become intense or disruptive, such as abnormal discharge, itching, soreness, and malodor. This combination is applied in clinical settings that involve acute or disruptive symptom patterns, such as the syndromic management of vaginal discharge.

“This triple-action approach offers supportive relief when symptoms intensify and short-term symptomatic assistance is needed.”

Used in situations involving episodic or fluctuating manifestations, the medication may assist with managing symptoms related to inflammatory or irritative states and may contribute to easing the overall symptom load, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Mixed Infections This combination is commonly used to help with managing symptoms when signs suggest an infection caused by a mixture of microbial types (bacteria, fungi, and/or protozoa).

Regulatory References

  1. Food And Drugs Authority Ghana

Eligibility and Restrictions for Use

Official Eligibility: Who Can and Cannot Use Triokit

Triokit (Omeprazole, Clarithromycin, and Tinidazole) eligibility is determined by the strictest limitations of its three components, as defined in official regulatory documents. Use is primarily restricted to Adults for the treatment of H. pylori and is subject to several absolute contraindications.


Absolute Contraindications

  • Allergy/Hypersensitivity: Patients with known allergy to Omeprazole, Clarithromycin, Tinidazole, any macrolide antibiotic, or related drugs.
  • Cardiac Risk: Individuals with a history of QT prolongation, ventricular arrhythmia, or uncorrected hypokalemia (due to the Clarithromycin component).
  • Organ/Blood Conditions: Patients with severe hepatic failure combined with renal impairment, a history of blood dyscrasias, or organic neurological disorders.

Restricted or Non-Recommended Use

  • Pregnancy and Lactation: The drug is contraindicated during pregnancy (especially the first trimester) and is not recommended for nursing mothers.
  • Age Groups: Safety and efficacy are not established in the pediatric population (children and adolescents), and use is restricted to adults.
  • Organ Impairment: Use is avoided in cases of severe hepatic impairment. Dose adjustments are typically required for moderate to severe renal impairment.

What should I know about interactions with other medicines?

Triokit Interactions with other medicines and products

This section outlines interactions with other medicines and products as documented in official government regulatory information for the components of Triokit (Azithromycin, Fluconazole, Secnidazole).

Formally Contraindicated Combinations

Certain combinations are explicitly prohibited due to the risk of serious adverse effects. The Fluconazole component is contraindicated for co-administration with drugs such as Terfenadine and Cisapride. Additionally, the Secnidazole component requires the strict avoidance of Alcoholic Beverages and Disulfiram.

Documented Pharmacokinetic Interactions

Interactions involving drug metabolism are documented, primarily due to Fluconazole’s ability to inhibit certain CYP enzymes. This can lead to increased plasma levels of co-administered medicines, including Phenytoin, Theophylline, and immunosuppressants like Cyclosporine. Conversely, co-administration with Rifampicin can reduce the exposure of Fluconazole. The absorption of the Azithromycin component is reduced by Antacids containing magnesium or aluminium.

Pharmacodynamic and Timing Constraints

Secnidazole may potentiate the effect of Coumarin anticoagulants like Warfarin, increasing the risk of bleeding. The Azithromycin component requires consideration of QT prolongation risk when taken with other proarrhythmic agents. To counteract reduced absorption, the product label requires that Antacids be administered at least 4 hours apart from the Azithromycin component.

Mechanism of Action

Triokit is a fixed-dose combination product containing fluconazole, azithromycin, and secnidazole, each modulating distinct molecular and cellular pathways within susceptible microorganisms.

Fluconazole acts as an inhibitor of the cytochrome P450-dependent enzyme 14 alpha-demethylase (CYP51) in fungi. This enzymatic inhibition disrupts the conversion of lanosterol to ergosterol, a vital component of the fungal cell membrane. The consequence is an alteration of membrane fluidity and permeability, which compromises structural integrity at the cellular level.

Azithromycin is a macrolide antibiotic that targets the 50S ribosomal subunit of susceptible bacteria and protozoa. It functions as an inhibitor of bacterial protein synthesis by blocking the transpeptidation process, leading to a downstream cascade that prevents polypeptide chain elongation and inhibits the assembly of essential structural and functional proteins.

Secnidazole is an antiprotozoal and antibacterial agent that, following metabolic activation, produces cytotoxic free radicals that interact with and damage the DNA and other macromolecules of the targeted organisms. This molecular interaction ultimately disrupts the nucleic acid structure and inhibits the synthesis of new DNA, resulting in the cessation of cellular replication and function. The overall system-level physiological consequence of these three distinct mechanisms is the simultaneous interruption of multiple pathogen-specific cellular processes.

Dosage and Administration Information

How Triokit is Used: Official Administration Guidelines

Triokit is a fixed-dose combination product containing Azithromycin, Fluconazole, and Secnidazole. Its usage is governed by a single-course, single-day regimen designed for oral administration.


Approved Dosing and Route

Component Dose Route of Administration
Azithromycin 1,000 mg (1 g) Oral
Fluconazole 150 mg Oral
Secnidazole 2,000 mg (2 g) Oral

The entire regimen is completed by swallowing all components of the kit—which are typically tablets—whole with water. The tablets must not be chewed, crushed, or broken.


Timing and Special Conditions

Official labeling provides specific instructions regarding meal timing to ensure proper absorption and tolerance:

  • Azithromycin: Should generally be taken 1 hour before a meal (on an empty stomach).
  • Secnidazole: Should be administered with or after food to help mitigate potential gastrointestinal upset.
  • Fluconazole: Can be taken independently of meals.

Since this is a single-day course, if the dose is missed or incomplete, official instructions advise taking the full missed dose as soon as it is remembered on the same day.

Population and Contextual Rules

The fixed-dose kit is not recommended for use in children (typically under 12 years of age or below 45 kg) due to the standardized adult dose. Furthermore, patients with severe hepatic impairment are typically advised against using the product. The official use instructions advise against drinking alcoholic beverages during and for up to 72 hours after the Secnidazole component.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Triokit

Evidence for Use in Syndromic Management of Abnormal Vaginal Discharge

Research has explored the use of this fixed-dose combination in clinical settings involving episodic or acute symptom patterns, such as the syndromic management of abnormal vaginal discharge. These studies, which include short-term randomized controlled trials (RCTs), were conducted during periods of increased symptom activity to examine the clinical and microbiological outcomes studied. Researchers focused on outcomes related to physical discomfort and changes in patient-reported experiences.

Studies monitored how symptoms evolved in the observed populations, with a focus on measuring both clinical cure (the resolution of patient symptoms like itching and malodor) and microbiological status (the presence or absence of the target pathogens). Where studies recorded endpoints related to clinical and microbiological status, these measurements were documented in some studies when assessed typically 1 to 2 weeks after treatment completion. Research provides insight into short-term changes, but the findings describe group patterns, not personal outcomes.

Evidence for Specific Component Infections (Bacterial Vaginosis, Candidiasis, Trichomoniasis)

The evidence supporting Triokit's components for treating specific conditions like Bacterial Vaginosis, Vaginal Candidiasis, and Trichomoniasis is derived from RCTs, systematic reviews, and meta-analyses of the individual active agents (Azithromycin, Fluconazole, and Secnidazole). These studies focused on established, single-pathogen diagnoses, with research examining the eradication of the identified organisms and the corresponding changes in clinical signs. Research describes that, individually, each agent was observed in some studies that monitored the target pathogen status. However, comparative evidence specifically examining the triple fixed-dose combination structure versus other single-agent regimens is limited.

What is Still Uncertain in the Research Landscape

One primary uncertainty is the syndromic management approach used in some trials, meaning patient enrollment often relied on symptom presentation rather than a confirmed laboratory diagnosis of all specific pathogens. Additionally, due to the limited follow-up durations, long-term outcomes and recurrence patterns are not fully established. Data for certain groups, such as adolescents or women with certain severe co-occurring medical conditions, remain insufficient.

Key Studies & References

  1. A Clinical Study to Assess the Effectiveness of Oral Combination Kit Therapy in Syndromic Management of Abnormal Vaginal Discharge (FEMINE Study) in Kinshasa, Democratic Republic of Congo
  2. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) - New treatment recommendations (WHO)
  3. Summary of Product Characteristics (SmPC) for Fast Kit (Azithromycin, Fluconazole, Secnidazole) - (Example Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Triokit (FAQ)


Q: How long does the full course of Triokit treatment usually last?

A: Triokit is designed as a single-course, single-day regimen for oral administration, as described in the official instructions. This means the entire treatment is completed within one day, making it intended for short-term use only.


Q: Can Triokit be used by pregnant or breastfeeding women?

A: Official product labeling advises that use of the components during pregnancy and breastfeeding should be discussed with a healthcare provider. The Secnidazole component, in particular, is not typically recommended during the first three months of pregnancy or while breastfeeding.


Q: What happens if I miss a dose of Triokit?

A: Since Triokit is a single-day regimen, regulatory instructions advise taking the full missed dose as soon as it is remembered on the same day. This approach ensures the components are received in the intended course.


Q: Will I need to change my diet while taking Triokit?

A: Official rules advise on specific meal timing for each component to optimize absorption and tolerance. Critically, it also requires the strict avoidance of alcoholic beverages during treatment and for up to 72 hours after the Secnidazole component. No other general dietary changes are explicitly mandated in the official documents.


Q: Does Triokit interact with common over-the-counter pain relievers like ibuprofen or aspirin?

A: The Fluconazole component may increase the exposure of some non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen. This may lead to changes in the action or effects of the pain reliever. The Azithromycin component is generally reported in regulatory documents to be safe with Ibuprofen.


Q: Does Triokit interact with supplements like vitamins or herbal remedies?

A: Official labeling for the Fluconazole component notes that it can affect the metabolism of many medicines due to its impact on certain CYP enzymes. Users of herbal or vitamin supplements are advised to inform a healthcare professional, as the potential for interactions exists even if they are not specifically detailed in the product information.


Q: Can taking Triokit affect the effectiveness of birth control pills?

A: Studies on the Fluconazole component suggest it may result in small increases in the levels of hormones found in some oral contraceptives. It is not likely to affect most contraception, but the official information suggests that patients seeking clarification about oral contraceptives may wish to discuss this with a healthcare provider.


Q: Can Triokit cause dizziness or affect my ability to drive?

A: Some of the components of Triokit have been associated with side effects such as dizziness or headache in official documents. Official information notes that patients who experience these effects may need to exercise caution when driving or operating machinery.


Q: Does Triokit contain penicillin?

A: No. Triokit is a combination product containing Azithromycin (a macrolide antibiotic), Fluconazole (an antifungal), and Secnidazole (an antibacterial and antiprotozoal). It is not described in official documents as containing penicillin.


Q: What should I expect in terms of how quickly Triokit starts working?

A: Although the three active components begin working at the cellular level soon after administration, improvement in symptoms typically varies based on the type and severity of the infection. Official sources and medical information indicate that improvement often begins within 1 to 3 days of starting treatment.


Q: What are the most common side effects people experience with Triokit?

A: Common side effects reported in the official product labeling for the components include: nausea, vomiting, diarrhea, headache, taste change, stomach pain, and dizziness.


Q: Is it normal to feel stomach discomfort or have diarrhea while taking Triokit?

A: Official regulatory documents list Gastrointestinal Disorders such as diarrhea, stomach pain, nausea, and vomiting among the reported side effects of the components. These effects are included in the official list of reported side effects.


Q: Can Triokit cause a metallic or unusual taste in the mouth?

A: Yes, a taste change (often described as metallic) is specifically listed in the official product documents as one of the reported side effects associated with the components.


Q: What are some common foods or drinks that should be avoided while taking Triokit?

A: The most critical avoidance stated in the official instructions is alcoholic beverages, which must not be consumed during treatment and for a period afterward. No other specific common foods are explicitly listed for avoidance in the official product labeling.


Q: Are there any serious side effects of Triokit that I should be aware of?

A: Official labeling for the components includes descriptions of rare, but serious, effects. These include severe skin reactions, liver damage, and allergic reactions (hypersensitivity). The official label describes situations that may warrant medical consultation, such as severe or sudden reactions.


Q: Will a test be required after treatment to confirm if the infection is gone?

A: For the conditions Triokit treats, while a routine 'test of cure' is not always necessary, some official treatment guidelines may recommend a rescreening at approximately 3 months after treatment. This is typically done to check for repeat infection.


Q: Can Triokit affect blood sugar levels for people with diabetes?

A: Official product information notes that the Fluconazole component may interact with some oral medicines used to treat diabetes, which can lead to changes in blood sugar levels. Official labeling suggests that patients with diabetes may need to monitor their blood sugar closely during treatment.


Q: Is it common to feel tired or fatigued while on Triokit?

A: Feelings of tiredness (asthenia) have been reported in some official documents as being associated with the Azithromycin component. This is considered a possible side effect, though it is not experienced by everyone.


Q: What is the importance of finishing the entire course of Triokit, even if I feel better?

A: Official guidance for antimicrobials emphasizes that taking the full prescribed course is necessary to eliminate all infectious microorganisms and to reduce the risk of resistance developing. Stopping treatment early may allow the infection to return.


Q: Can Triokit cause sun sensitivity or a rash when exposed to the sun?

A: The Fluconazole and Azithromycin components have been associated with a potential for developing a skin rash and increased sensitivity to sunlight (photosensitivity). Patients may wish to take protective measures against sun exposure, as indicated in the official labeling.


Q: Is it better to take Triokit with food or on an empty stomach?

A: The kit requires taking the Azithromycin component 1 hour before a meal (on an empty stomach) and the Secnidazole component with or after food to help reduce potential stomach upset. The Fluconazole component can be taken independently of meals.


Q: Does Triokit cause a yeast infection or thrush?

A: The official list of side effects includes the potential for developing a vaginal infection (often a yeast infection or thrush) as a reported side effect of the components. This is a potential consequence of the antibiotics affecting the body's natural flora.

How should Triokit be stored and disposed of?

Triokit (Azithromycin, Fluconazole, Secnidazole) storage must comply with regulatory requirements to preserve product integrity.

Storage Conditions

Temperature and Environment: The tablets must be stored at a temperature below 30°C in a cool and dry place. Protection from direct light and moisture is mandatory.

Packaging and Safety: Keep the medicine in its original, tightly closed container and store it out of the reach and sight of children.

Disposal Instructions

Unused product must be disposed of according to the specific instructions provided on the regulatory label or packaging. Disposal must also ensure the product is not consumed accidentally by children or pets. Consult a healthcare professional or local waste authority for guidance if specific instructions are unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Triokit found in:

A-Z Index: